News | January 09, 2025
Evonik partners with South Korean ST Pharm to increase its offerings for RNA and nucleic acid delivery
Increases speed to market for drug developers working on nucleic acid therapeutics
Increases speed to market for drug developers working on nucleic acid therapeutics
Acquisition expands high-value medical platform
This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
He has 29+ years’ comprehensive experience in world-class Formulations and API (for US and EU requirements) mainly related to injectables
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
Smeeta Bhatkal, Santosh Desai and Akshay Kumar join as Independent Directors; Shaina NC as Non-Executive Director
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
The transaction is expected to result in approximately $175 million to support further development of IMG-007
The investment will empower RDHL to develop a virtual diagnostic and care platform, expanding access to healthcare for underserved communities
Subscribe To Our Newsletter & Stay Updated
